Austalia's Mesoblast rises most in three weeks as Q2 loss narrow

Mesoblast

28/02/2023 03:08

** Shares of Ausrtalia's Mesoblast  MSB.AX  rise as much as
8.6% to A$1.01, set to gain most since Feb 9
    ** The drug developer's Q2 loss attributable narrows to
$24.5 mln from $25.9 mln a year ago
    ** Q2 revenue dips to $2.1 mln from $2.4 mln
    ** ~2 mln shares change hands, topping 30-day avg of 1.7 mln
    ** Stock has risen 6.9% this year, as of last close

 (Reporting by Rishav Chatterjee in Bengaluru)
 ((Rishav.Chatterjee@thomsonreuters.com;))